WCN26-6783 ORIGIN EXTEND: A LONG-TERM EXTENSION STUDY OF ATACICEPT IN IgA NEPHROPATHY

Read full text Summarise with VIRAT
Authors: Richard A. Lafayette, Robert Brenner, Laura Jiang, Jonathan Barratt
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy is a B-cell mediated disease associated with progressive, irreversible loss of kidney function and a high lifetime risk of kidney failure. Atacicept is a native human TACI-Fc fusion protein that binds B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), the key cytokines that drive B-cell activation central to the pathophysiology of IgA nephropathy. Atacicept is currently in late-stage clinical development for IgAN treatment. The ORIGIN Phase 2b study met the primary endpoint demonstrating a statistically significant and clinically meaningful UPCR reduction with atacicept compared to placebo at 24 weeks, with a further reduction and eGFR stabilization through 36 weeks.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106278–106278
Publication date
25 March 2026
Language
EN